Bristol-Myers Squibb and Exelixis have entered a global collaboration covering two novel anti-cancer molecules. Bristol-Myers Squibb agreed to pay Exelixis an upfront cash payment of $195 million for the development and commercialization rights to two Exelixis molecules: XL184, a small molecule inhibitor of MET, VEGFR2 and RET, which is currently in Phase III development for medullary thyroid cancer, and XL281, a small molecule inhibitor of RAF kinase, which is currently in Phase I development f...